10th August at 11am – Launch meeting – Hosted by Jessica Turner, Leukaemia Care North-West Regional Coordinator.
Our Acute Myeloid Leukaemia (AML) North Virtual Support Group is for anyone who has been diagnosed with AML in the North of England. Our meetings are a great way for you to meet someone who is going through or has been through the same journey as you. .
Guest: Laura de la Harpe, Registered Nutritional Therapist and Nutritionist
If you would like further information or if you would like to attend, please contact our Patient Services Team on freephone 08088 010 444 (Monday – Friday, 9am-5pm) or email support@leukaemiacare.org.uk
Written by
HAIRBEAR_UK
Administrator
To view profiles and participate in discussions please or .
Gain insight on the latest investigative treatments for patients with FLT3-positive AML with this expert commentary.
"Approximately 25% of patients with acute myeloid leukemia (AML) have the FLT3-ITD or FLT3-TKD mutation, which is prognostic for poorer outcomes. In the past 4 years, the FDA approved 2 FLT3 inhibitors, midostaurin and gilteritinib. Midostaurin was approved in combination with standard 3+7 induction chemotherapy, in a randomized, multicentral phase III study of 3+7 with midostaurin vs 3+7 alone in patients with newly diagnosed FLT3-ITD and/or DA35 mutations in the frontline setting. Gilteritinib is a more potent and specific second-generation FLT3 inhibitor and was approved based on improved survival as well as improved composite CR (CRc) rate, noted in the phase III Admiral study in patients with relapsed/refractory FLT3-ITD–mutated and/or D835-mutated AML, in which gilteritinib was compared with investigator choice chemotherapy, and gilteritinib showed a significantly improved CRc rate of 35% vs 15% for chemotherapy."
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.